|
1
|
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
|
Science
|
2010
|
10.78
|
|
2
|
Detection of circulating tumor DNA in early- and late-stage human malignancies.
|
Sci Transl Med
|
2014
|
8.36
|
|
3
|
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
|
Proc Natl Acad Sci U S A
|
2013
|
6.88
|
|
4
|
Colorectal cancer: mutations in a signalling pathway.
|
Nature
|
2005
|
5.42
|
|
5
|
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
|
Science
|
2004
|
4.67
|
|
6
|
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.
|
Proc Natl Acad Sci U S A
|
2008
|
4.13
|
|
7
|
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
|
Am J Pathol
|
2009
|
3.90
|
|
8
|
Notch signaling, gamma-secretase inhibitors, and cancer therapy.
|
Cancer Res
|
2007
|
3.07
|
|
9
|
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
|
Am J Surg Pathol
|
2005
|
2.83
|
|
10
|
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
|
Cancer Biol Ther
|
2006
|
2.76
|
|
11
|
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
|
Cancer Res
|
2011
|
2.71
|
|
12
|
Notch3 gene amplification in ovarian cancer.
|
Cancer Res
|
2006
|
2.66
|
|
13
|
MicroRNA expression and identification of putative miRNA targets in ovarian cancer.
|
PLoS One
|
2008
|
2.60
|
|
14
|
Three classes of genes mutated in colorectal cancers with chromosomal instability.
|
Cancer Res
|
2004
|
2.51
|
|
15
|
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma.
|
Proc Natl Acad Sci U S A
|
2005
|
2.29
|
|
16
|
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion.
|
Cancer Res
|
2008
|
2.26
|
|
17
|
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
|
Cancer Res
|
2009
|
2.25
|
|
18
|
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
|
J Natl Cancer Inst
|
2012
|
2.09
|
|
19
|
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
|
Am J Surg Pathol
|
2011
|
2.03
|
|
20
|
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
|
J Pathol
|
2011
|
1.94
|
|
21
|
Identifying tumor origin using a gene expression-based classification map.
|
Cancer Res
|
2003
|
1.78
|
|
22
|
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
|
Clin Cancer Res
|
2010
|
1.71
|
|
23
|
Amplicon profiles in ovarian serous carcinomas.
|
Int J Cancer
|
2007
|
1.70
|
|
24
|
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
|
Cancer Res
|
2004
|
1.66
|
|
25
|
Light response of retinal ON bipolar cells requires a specific splice variant of Galpha(o).
|
J Neurosci
|
2002
|
1.62
|
|
26
|
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
|
Clin Cancer Res
|
2006
|
1.62
|
|
27
|
Digital karyotyping.
|
Nat Protoc
|
2007
|
1.58
|
|
28
|
Low-grade serous carcinomas of the ovary contain very few point mutations.
|
J Pathol
|
2011
|
1.56
|
|
29
|
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
|
Cancer Res
|
2005
|
1.55
|
|
30
|
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival.
|
Proc Natl Acad Sci U S A
|
2006
|
1.52
|
|
31
|
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
|
Am J Pathol
|
2010
|
1.45
|
|
32
|
Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.
|
Am J Surg Pathol
|
2010
|
1.44
|
|
33
|
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.
|
Cancer Res
|
2009
|
1.36
|
|
34
|
Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
|
Am J Surg Pathol
|
2009
|
1.34
|
|
35
|
Homozygous deletion of MKK4 in ovarian serous carcinoma.
|
Cancer Biol Ther
|
2006
|
1.32
|
|
36
|
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
|
Clin Cancer Res
|
2004
|
1.27
|
|
37
|
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
|
Neoplasia
|
2012
|
1.22
|
|
38
|
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer.
|
Cancer Res
|
2005
|
1.22
|
|
39
|
Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
|
Oncotarget
|
2010
|
1.21
|
|
40
|
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.
|
Am J Obstet Gynecol
|
2010
|
1.20
|
|
41
|
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.
|
Cancer Res
|
2009
|
1.20
|
|
42
|
Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma.
|
Hum Pathol
|
2006
|
1.18
|
|
43
|
A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
|
J Pathol
|
2014
|
1.17
|
|
44
|
The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1.
|
Cancer Res
|
2008
|
1.16
|
|
45
|
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.
|
Proc Natl Acad Sci U S A
|
2013
|
1.16
|
|
46
|
NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor.
|
Cancer Res
|
2007
|
1.16
|
|
47
|
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
|
Clin Cancer Res
|
2006
|
1.14
|
|
48
|
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.
|
Hum Mutat
|
2006
|
1.12
|
|
49
|
Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability.
|
J Biol Chem
|
2010
|
1.10
|
|
50
|
Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
|
Am J Pathol
|
2011
|
1.08
|
|
51
|
Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer.
|
Cancer Res
|
2008
|
1.07
|
|
52
|
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.
|
J Oncol
|
2010
|
1.07
|
|
53
|
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
|
PLoS One
|
2010
|
1.06
|
|
54
|
Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
|
Mod Pathol
|
2011
|
1.05
|
|
55
|
Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome.
|
Hum Pathol
|
2005
|
1.04
|
|
56
|
Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
|
Int J Gynecol Pathol
|
2012
|
1.02
|
|
57
|
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
|
Gynecol Oncol
|
2006
|
1.00
|
|
58
|
Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
|
Am J Surg Pathol
|
2013
|
1.00
|
|
59
|
Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma.
|
Am J Pathol
|
2011
|
0.99
|
|
60
|
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
|
J Cell Mol Med
|
2011
|
0.98
|
|
61
|
Defining NOTCH3 target genes in ovarian cancer.
|
Cancer Res
|
2012
|
0.97
|
|
62
|
The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.
|
Am J Surg Pathol
|
2012
|
0.96
|
|
63
|
Apply innovative technologies to explore cancer genome.
|
Curr Opin Oncol
|
2005
|
0.96
|
|
64
|
Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.
|
Mod Pathol
|
2011
|
0.96
|
|
65
|
Identification of microbial DNA in human cancer.
|
BMC Med Genomics
|
2009
|
0.95
|
|
66
|
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
|
Hum Pathol
|
2007
|
0.94
|
|
67
|
NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells.
|
Cancer Res
|
2012
|
0.93
|
|
68
|
Generation and characterization of an ascitogenic mesothelin-expressing tumor model.
|
Cancer
|
2007
|
0.93
|
|
69
|
Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.
|
J Pathol
|
2013
|
0.89
|
|
70
|
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.
|
Gynecol Oncol
|
2012
|
0.89
|
|
71
|
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.
|
Clin Cancer Res
|
2007
|
0.87
|
|
72
|
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
|
J Pathol
|
2014
|
0.87
|
|
73
|
Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.
|
PLoS One
|
2012
|
0.87
|
|
74
|
Expression of extracellular matrix proteins in ovarian serous tumors.
|
Int J Gynecol Pathol
|
2007
|
0.86
|
|
75
|
Integrative network analysis to identify aberrant pathway networks in ovarian cancer.
|
Pac Symp Biocomput
|
2012
|
0.85
|
|
76
|
High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
|
Gynecol Oncol
|
2012
|
0.84
|
|
77
|
Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
|
Hum Pathol
|
2008
|
0.84
|
|
78
|
The role of forkhead box Q1 transcription factor in ovarian epithelial carcinomas.
|
Int J Mol Sci
|
2012
|
0.83
|
|
79
|
Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.
|
Am J Pathol
|
2012
|
0.83
|
|
80
|
Ovarian cancer specific kallikrein profile in effusions.
|
Gynecol Oncol
|
2007
|
0.83
|
|
81
|
New determinates of disease progression and outcome in metastatic ovarian carcinoma.
|
Histol Histopathol
|
2010
|
0.83
|
|
82
|
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions.
|
Hum Pathol
|
2011
|
0.82
|
|
83
|
Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.
|
Am J Pathol
|
2005
|
0.82
|
|
84
|
Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.
|
Int J Gynecol Pathol
|
2011
|
0.82
|
|
85
|
Mapping DNA quantity into electrophoretic mobility through quantum dot nanotethers for high-resolution genetic and epigenetic analysis.
|
ACS Nano
|
2011
|
0.81
|
|
86
|
Digital karyotyping: an update of its applications in cancer.
|
Mol Diagn Ther
|
2006
|
0.81
|
|
87
|
Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma.
|
Biochim Biophys Acta
|
2005
|
0.80
|
|
88
|
Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
|
J Pathol
|
2011
|
0.80
|
|
89
|
Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.
|
Hum Pathol
|
2008
|
0.80
|
|
90
|
Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis.
|
PLoS One
|
2013
|
0.80
|
|
91
|
An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
|
PLoS One
|
2013
|
0.77
|
|
92
|
Air-stable and phosphine-free iridium catalysts for highly enantioselective hydrogenation of quinoline derivatives.
|
Org Lett
|
2008
|
0.77
|
|
93
|
Biomarker identification by knowledge-driven multilevel ICA and motif analysis.
|
Int J Data Min Bioinform
|
2009
|
0.76
|
|
94
|
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
|
Int J Gynecol Pathol
|
2017
|
0.76
|
|
95
|
Correction: Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube.
|
PLoS One
|
2016
|
0.75
|
|
96
|
[Anatomy of locating the internal auditory canal through the middle fossa approach with the assistance of high resolution CT].
|
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
|
2008
|
0.75
|
|
97
|
GIST: a Gibbs sampler to identify intracellular signal transduction pathways.
|
Conf Proc IEEE Eng Med Biol Soc
|
2011
|
0.75
|
|
98
|
Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange.
|
Biotechniques
|
2013
|
0.75
|